DoW Neurofibromatosis Exploration-Hypothesis Development Award
This grant funds early-stage, innovative research projects in neurofibromatosis that explore bold, testable hypotheses to lay groundwork for future scientific studies.
Funder: Defense Health Agency Contracting Activity - DHACA
Due Dates: September 8, 2026: Pre-Application (Letter of Intent) | September 22, 2026: Full Application | September 28, 2026: End of Application Verification Period
Funding Amounts: ~$1.28M total for ~8 awards; max $160,000 total costs per award for up to 2 years
Summary: Supports innovative, high-risk exploratory research in neurofibromatosis (NF) to lay the groundwork for future scientific investigation.
Key Information: Clinical trials are not allowed; open to all organizations and investigators at any career stage.
Description
This opportunity supports the initial exploration of innovative, high-risk, and potentially groundbreaking concepts in neurofibromatosis (NF) research. The intent is to enable early-stage studies that lay the groundwork for future research avenues, with an emphasis on innovation and scientific rigor. Projects should propose a well-formulated, testable hypothesis with strong rationale and study design. The program encourages novel paradigms and approaches that have the potential for significant impact on the understanding, diagnosis, or treatment of NF, including NF1, NF2, and schwannomatosis.
